Results 71 to 80 of about 5,561 (172)

Renal function in β-thalassemia major receiving desferal versus deferasirox [PDF]

, 2018
Introduction: Deferasirox is a new oral iron chelating agent which has been administered in β-thalassemia major patients in last few years. There is some reports regarding nephrotoxicity of this agent; however, no comparative study has been conducted ...
Azarkeivan, A., Sabzghabaei, F., Darnahal, M.   +2 more
core  

Effect Of Particle Size And Surfactant On The Solubility, Permeability And Dissolution Characteristics Of Deferasirox

, 2019
Deferasirox is an oral iron chelator used for the treatment of chronic iron overload in blood transfusions. Deferasirox is a BCS Class II drug with low solubility and high permeability. In the formulation development stage for BCS Class II compounds, one
Izat, Nihan, Oner, Levent, Akdag, Yagmur, Sahin, Selma, Gulsun, Tugba   +4 more
core   +2 more sources

Activity of Deferasirox in Mucorales: Influences of Species and Exogenous Iron

, 2011
Differences in deferasirox susceptibility among members of the order Mucorales are unknown. Here we show that Cunninghamella bertholletiae (four isolates) and Mucor species (five isolates) display higher deferasirox MICs and minimal fungicidal ...
Albert, Nathaniel, Lewis, Russell E., LEWIS, RUSSEL EDWARD, G. N. Pongas, Walsh, Thomas J., Nathaniel Albert, Pongas, Georgios N., Russell E. Lewis, R. Ben Ami, Thomas J. Walsh, N. Albert, T. J. Walsh, Georgios N. Pongas, Ben-Ami, Ronen, Ronen Ben-Ami, Kontoyiannis, Dimitrios P., Dimitrios P. Kontoyiannis, D. P. Kontoyiannis   +17 more
core   +1 more source

Brazilian bulletin for health technology assessment: deferasirox for iron overload [PDF]

, 2011
Objetivo: Avaliar a evidência de eficácia e segurança do deferasirox para o tratamento da sobrecarga de ferro relacionada à betatalassemia, doença falciforme e síndrome mielodisplásica, em comparação a outros quelantes de ferro disponíveis no Brasil ...
Silva, Marcus Tolentino [UNIFESP]
core  

Deferasirox Removes Cardiac Iron and Attenuates Oxidative Stress in the Iron-overloaded Gerbil

, 2009
Iron-induced cardiovascular disease is the leading cause of death in iron-overloaded patients. Deferasirox is a novel, once daily oral iron chelator that was recently approved for the treatment of transfusional iron overload. Here, we investigate whether
Al-Rousan, Rabaa M., Blough, Eric R., Paturi, Satyanarayana, Kakarla, Sunil K., Walker, Ernest M., Gutta, Anil K., Laurino, Joseph P.   +6 more
core   +1 more source

Fluvastatin suppresses hemin-induced cell death, reactive oxygen species generation, and elevated labile iron pool

Hematology, Transfusion and Cell Therapy
Background: In transfusion-related iron overload, macrophage/reticuloendothelial cells are the first site of haem-derived iron accumulation. The prevention of haem-induced cytotoxicity in macrophages may represent a target for iron overload treatment ...
Shion Imoto, Katsuyasu Saigo, Mari Kono, Ayako Ohbuchi, Tohru Sawamura, Yuji Mizokoshi, Takashi Suzuki   +6 more
doaj   +1 more source

Efektivitas Deferasirox pada Pasien Thalasemia Mayor: Artikel Review: Efficacy of Deferasirox for Thalassemia Mayor: Review Article

Thalassemia is a heterogeneous grouping of genetic disorders resulting from decreased synthesis of the alpha or beta chains of hemoglobin. Anemia and iron overload are the main causes of morbidity and mortality due to thalassemia disease.
Zulkarnaen, Bambang Subakti, Arfie, Naksa Garnida, Sudarmanto   +2 more
core   +1 more source

Pharmacokinetics, Distribution, Metabolism, and Excretion of Deferasirox and its Iron Complex in Rats

, 2008
Deferasirox (Exjade®, ICL670, CGP72670) is an iron-chelating drug for oral treatment of transfusional iron-overload in patients suffering from β-thalassemia or sickle cell disease. The pharmacokinetics and disposition of deferasirox were investigated in
T. Faller, Waldmeier, Felix, G. J. M. Bruin, Boernsen, K. Olaf, F. Waldmeier, Nick, Hanspeter, Faller, Thomas, H. Wiegand, A. Schweitzer, Wiegand, Hansjoerg, Schweitzer, Alain, Bruin, Gerardus, K.-O. Boernsen, J. Schneider, H. Nick, Schneider, Josef   +15 more
core   +1 more source

Once-daily oral deferasirox for the treatment of transfusional iron overload

, 2008
The increasing use of blood transfusions, combined with extended patient survival, has led to an increase in the number of patients at risk of developing transfusional iron overload.
Galanello R, ORIGA, RAFFAELLA
core   +1 more source

MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine

, 2018
We prospectively assessed the efficacy of deferasirox versus deferiprone or desferrioxamine as monotherapy in thalassaemia major (TM) patients by magnetic resonance imaging (MRI).
D'Ascola D. G., Restaino G., Meloni A., Lisi R., Mangione M., Pepe A., Cuccia L., Pistoia L., Gamberini M. R., Ricchi P., Righi R., Rosso R., Allo M., Positano V., Spasiano A.   +14 more
core   +1 more source